Patrick Cohen

4PUBLICATIONS
20CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Ngā pūtaiao koiora-hauora, haumanu hoki o te Māori (Māori biomedical and clinical sciences)Health and ecological risk assessment
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Jun 18, 2024
Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Primary Results From AMEERA-5.

Javier Cortés, Sara A Hurvitz, Joyce O'Shaughnessy

|Apr 01, 2024
Joint modeling of tumor dynamics and progression-free survival in advanced breast cancer: Leveraging data from amcenestrant early phase I-II trials.

Marc Cerou, Hoai-Thu Thai, Laure Deyme

|Oct 30, 2023
Reply to Y. Yoshitomi et al.

Sara M Tolaney, Elisabeth De Kermadec, Patrick Cohen

|Jun 22, 2023
AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.

Sara M Tolaney, Arlene Chan, Katarina Petrakova

Pageof 1

Frequent Collaborators

3 joint publications

Gautier Paux

2 joint publications

Sara M Tolaney

2 joint publications

Suzette Delaloge

2 joint publications

Hiroji Iwata